MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, penicillin-intermediate S. pneumoniae, and vancomycin-resistant enterococci. MRX-I demonstrated comparable or slightly higher activity than linezolid and was active against enterococci resistant to both vancomycin and teicoplanin. In addition, MRX-I exhibited bactericidal activities against staphylococci and streptococci but was bacteriostatic against enterococci. MRX-I inhibits formation of functional 70S initiation complex essential for bacterial protein synthesis, leading to the cessation of bacterial growth. Oral MRX-I was associated with a greater bioavailability and exposure when administered with food, and minimal accumulation of MRX-I occurred after multiple-dose administration. Oral MRX-I was well tolerated at single doses of up to 1,200 and 800 mg q12h for up to 28 days; all adverse events were mild to moderate in severity, and there was no drug discontinuation due to adverse events.

MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, penicillin-intermediate S. pneumoniae, and vancomycin-resistant enterococci. MRX-I demonstrated comparable or slightly higher activity than linezolid and was active against enterococci resistant to both vancomycin and teicoplanin. In addition, MRX-I exhibited bactericidal activities against staphylococci and streptococci but was bacteriostatic against enterococci. MRX-I inhibits formation of functional 70S initiation complex essential for bacterial protein synthesis, leading to the cessation of bacterial growth. Oral MRX-I was associated with a greater bioavailability and exposure when administered with food, and minimal accumulation of MRX-I occurred after multiple-dose administration. Oral MRX-I was well tolerated at single doses of up to 1,200 and 800 mg q12h for up to 28 days; all adverse events were mild to moderate in severity, and there was no drug discontinuation due to adverse events.

JNJ-872 is an inhibitor of influenza virus replication that offers a potential for the treatment of pandemic and seasonal influenza.

Remacemide is a low-affinity noncompetitive NMDA receptor antagonist with sodium channel blocking properties. It has been studied for a number of conditions including acute ischemic stroke, epilepsy, Parkinsons Disease, and Huntington's disease. It was concluded, that was unlikely that remacemide would be further developed as an antiepileptic drug. As for other conditions, there no any information in the literature, why remacemide is no longer being developed for them.

Remacemide is a low-affinity noncompetitive NMDA receptor antagonist with sodium channel blocking properties. It has been studied for a number of conditions including acute ischemic stroke, epilepsy, Parkinsons Disease, and Huntington's disease. It was concluded, that was unlikely that remacemide would be further developed as an antiepileptic drug. As for other conditions, there no any information in the literature, why remacemide is no longer being developed for them.

Miroprofen, an imidazopyridine derivative, possesses anti-inflammatory properties. It was shown that this compound could be effective in suppressing pain responses and acute inflammation accompanied by increased vascular permeability. Analgesic effect of this compound was studied in post-extraction pain. However, information about the current study of this agent is not available.

Jiangsu HengRui Medicine Co. is developing SHR-117887, an orally active dipeptidyl peptidase-4 (CD26 antigen) inhibitor for the treatment of type 2 diabetes. SHR-117887 is a potent DPP-4 inhibitor that improves metabolic control and β-cell function in diabetic rodent models. SHR-117887 is in phase II clinical trials for the treatment of type 2 diabetes.

GSK-2269557 (nemiralisib), a PI3Kδ inhibitor, is in development as an anti-inflammatory drug for the treatment of inflammatory airways disease. Studies in moderate or severe stable COPD patients have shown an acceptable safety and tolerability profile when GSK-2269557 was administered via inhalation. Cough was the most commonly reported adverse event.